Across 13 studies and 958 patients, HBOT added to standard medication improved Parkinson’s motor scores (UPDRS III, mean difference -2.96) and roughly tripled the odds of clinical response.1 The evidence is real but comes almost entirely from Chinese trials with high heterogeneity, and no Western sham-controlled RCT has confirmed it. HBOT is an add-on to levodopa, never a replacement. It is one of several brain and cognitive conditions studied with HBOT.
What Does the Research Say?
The most comprehensive human data comes from two recent meta-analyses. Bu et al. (2024) analyzed 13 studies with 958 participants drawn from PubMed, Web of Science, Cochrane Library, and Chinese databases through March 2023.1 The results consistently favored HBOT as an adjunct across motor and non-motor outcomes.
HBOT Adjunct Outcomes in Parkinson’s (Bu et al., 2024)
| Outcome | Effect | Interpretation |
|---|---|---|
| Motor function (UPDRS III) | MD -2.96 (95% CI -4.31 to -1.61) | Reduced motor severity |
| Disease stage (Hoehn-Yahr) | MD -0.14 (95% CI -0.26 to -0.02) | Small stage improvement |
| Cognition (MoCA) | SMD 0.65 (95% CI 0.45 to 0.85) | Moderate-to-large effect |
| Sleep quality (PSQI) | MD -2.52 (95% CI -2.85 to -2.18) | Better sleep |
| Daytime sleepiness (ESS) | MD -3.30 (95% CI -3.77 to -2.83) | Less sleepiness |
| Treatment response rate | OR 3.18 (95% CI 1.60 to 6.33) | ~3x odds of response |
Odds of clinical response with HBOT versus control in Parkinson’s patients across 13 studies.
Bu et al., 2024, Dementia and Geriatric Cognitive Disorders
The Pan et al. (2025) meta-analysis focused on non-motor symptoms across 16 studies with 1,324 participants.2 HBOT was associated with reduced anxiety (Hamilton Anxiety Scale) and depression (Hamilton Depression Scale), improved cognition (MoCA, MMSE), better sleep (PSQI, ESS), and improved swallowing, with motor function also improving. Both meta-analyses report significant heterogeneity and draw predominantly from Chinese research literature, which is the central caveat on all of these numbers.
Reduction in UPDRS III motor score with HBOT adjunct across 958 patients, a clinically meaningful change.
Bu et al., 2024
How Might HBOT Protect Dopamine Neurons?
Parkinson’s is defined by progressive loss of dopaminergic neurons in the substantia nigra. By the time motor symptoms appear, roughly 60 to 80% of these neurons are already gone. The mechanistic case for HBOT rests on mitochondrial dysfunction, oxidative stress, and neuroinflammation, the same processes HBOT is known to influence. Parkinson’s sits within a wider family of brain disorders in our overview of HBOT for neurological conditions.
A 2022 mechanistic study in the MPTP mouse model, the standard Parkinson’s animal model, found that 7 days of HBOT at 2.5 ATA (1 hour daily) produced measurable biological effects: more surviving dopaminergic (TH-positive) neurons in the substantia nigra, higher BDNF, less apoptotic signaling, reduced inflammatory mediators, improved locomotor activity and grip strength, and upregulated mitochondrial biogenesis through the SIRT-1/PGC-1alpha/TFAM pathway.3
Mitochondrial biogenesis pathway upregulated by HBOT in Parkinson’s animal models, a plausible link to the clinical improvements.
Hsu et al., 2022, Biomolecules
The SIRT-1/PGC-1alpha pathway is a recognized regulator of mitochondrial health, and because mitochondrial failure is central to Parkinson’s pathology, this finding provides a biologically plausible rationale for the human results. Even mild hyperbaric oxygen, at pressures below standard clinical protocols, preserved dopaminergic neurons and improved balance-beam performance in the MPTP mouse.4 That said, none of these neuroprotective effects has been demonstrated in human tissue or imaging, so the mechanism remains animal-level evidence.
What the Research Does Not Show
Several limitations must be stated plainly, because they define how much weight the positive numbers can carry.
- No Western RCTs: as of 2026, no large double-blind sham-controlled trials have been conducted outside China. A systematic review protocol published in 2024 suggested one may be forthcoming.
- No confirmed neuron preservation in humans: the neuroprotective effects seen in animal models have not been shown in human tissue or imaging studies.
- Protocol heterogeneity: studies use different pressures, session lengths, and frequencies, which makes pooling and comparison difficult and inflates uncertainty.
- Adjunct only: all clinical evidence positions HBOT as an add-on to dopaminergic medication (levodopa, dopamine agonists), not a replacement. Animal work suggests combined HBOT plus levodopa may outperform either alone.5
What Does the HBOT Protocol Look Like?
The human studies in the Bu 2024 meta-analysis typically used hard-chamber protocols. Soft chambers at 1.3 ATA have not been validated in Parkinson’s research.
- Pressure: 2.0 to 2.5 ATA in clinical hard chambers
- Session duration: 60 minutes
- Frequency: 5 sessions per week
- Course length: 20 to 40 sessions (4 to 8 weeks)
For comparison, the Harch and Efrati protocols used in TBI and cognitive research run longer (40 to 60 sessions). Whether longer courses would yield greater or more durable benefit in Parkinson’s is untested. For what sessions involve, see our HBOT sessions guide, and for related applications, our pages on HBOT for brain injury and HBOT for dementia.
What Does HBOT for Parkinson’s Cost?
- Insurance: does not cover HBOT for Parkinson’s, which is an off-label use. See our HBOT insurance guide.
- Cost: a 40-session course typically runs $6,000 to $12,000 out of pocket. See our HBOT cost guide.
- Access: a hard chamber at 2.0 ATA or higher is required, usually at a specialized HBOT clinic or hospital-based program.
Who Should Not Try HBOT?
HBOT is generally safe when administered by trained professionals, but it is not appropriate for everyone. Discuss your full medical history with your provider first. It should not be used with an untreated pneumothorax (collapsed lung), where pressure changes can be life-threatening, or alongside certain chemotherapy drugs (bleomycin, cisplatin, doxorubicin, disulfiram).
Extra precautions may be needed with an upper respiratory infection or sinus congestion, a seizure disorder, COPD, high fever, a history of ear surgery, claustrophobia, or pregnancy. Always consult your physician before starting, especially if you take insulin or have a pacemaker. See our full guide to HBOT side effects and risks.
Frequently Asked Questions
Does HBOT slow the progression of Parkinson’s disease?
There is no human evidence that HBOT slows Parkinson’s progression. Animal studies (Hsu et al., 2022) found HBOT can preserve dopaminergic neurons and boost mitochondrial biogenesis via the SIRT-1/PGC-1alpha pathway (Hsu et al., 2022), but disease-slowing has never been confirmed in human tissue or imaging. Meta-analyses show symptom improvement as an adjunct (Bu et al., 2024), not a change in the underlying disease course. Treat any disease-modifying claim with caution.
Can HBOT replace levodopa for Parkinson’s?
No. Every study positions HBOT as an add-on to dopaminergic medication, not a substitute. Animal work even suggests HBOT combined with levodopa may work better than either alone (Pan et al., 2015). Stopping or reducing Parkinson’s medication in favor of HBOT is not supported by evidence and could be harmful. Any HBOT trial should be coordinated with the neurologist managing your medication.
Why is the Parkinson’s HBOT evidence considered weak?
The positive meta-analyses draw almost entirely from Chinese trials with significant heterogeneity in pressure, session length, and frequency (Bu et al., 2024; Pan et al., 2025). No large Western double-blind sham-controlled RCT has been completed, and sham-controlling HBOT is difficult because patients may sense pressure changes. The effect sizes are encouraging, but the quality and independence of the evidence keep it at a moderate rather than strong grade.
Sources
- Bu S, Liu W, Sheng X, Jin L, Zhao Q. “Hyperbaric Oxygen Therapy Improves Motor Symptoms, Sleep, and Cognitive Dysfunctions in Parkinson’s Disease.” Dementia and Geriatric Cognitive Disorders, 2024. 10.1159/000542619
- Pan Z, Tan W, Ran X, et al. “Effect of hyperbaric oxygen therapy for non-motor symptoms among patients with Parkinson’s disease: A systematic review and meta-analysis.” Clinical Rehabilitation, 2025. 10.1177/02692155241310750
- Hsu HF, Yang YL, Chang WH, et al. “Hyperbaric Oxygen Therapy Improves Parkinson’s Disease by Promoting Mitochondrial Biogenesis via the SIRT-1/PGC-1alpha Pathway.” Biomolecules, 2022;12(5):661. 10.3390/biom12050661
- Kusuda Y, Takemura A, Nakano M, Ishihara A. “Mild hyperbaric oxygen inhibits the decrease of dopaminergic neurons in the substantia nigra of mice with MPTP-induced Parkinson’s disease.” Neuroscience Research, 2018;132:58-62. PMID 29196223
- Pan X, Chen C, Huang J, Wei H, Fan Q. “Neuroprotective effect of combined therapy with hyperbaric oxygen and madopar on 6-OHDA-induced Parkinson’s disease in rats.” Neuroscience Letters, 2015;600:220-225. 10.1016/j.neulet.2015.06.030
- Atzeni F, et al. “Hyperbaric oxygen therapy in fibromyalgia and the diseases involving the central nervous system.” Clinical and Experimental Rheumatology, 2020. PMID 32116209
- Banou E. “Hyperbaric Oxygen Therapy Effect on ‘Kinesia Paradoxa’ Brain Circuits.” Advances in Experimental Medicine and Biology, 2021. 10.1007/978-3-030-78787-5_19
Medical Disclaimer
The content on BaricBoost.com is for informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
Author
Seph Fontane Pennock is the founder of BaricBoost.com and Regenerated.com, a clinic directory for regenerative medicine serving 10,000+ providers across the United States. He previously built and sold PositivePsychology.com, which grew to 19 million users and became the largest evidence-based positive psychology resource on the web. Seph brings direct experience as an HBOT patient, having completed protocols at clinics across three continents while navigating mold illness, systemic inflammation, and autoimmune conditions. His treatment journey includes hyperbaric oxygen therapy, peptide protocols, NAD+ therapy, and consultations with specialists from Dubai to Cape Town to Mexico. This combination of entrepreneurial track record and lived patient experience shapes everything published on BaricBoost.com. Every article is grounded in peer-reviewed research, informed by real clinical encounters, and written for patients making high-stakes treatment decisions. Seph's focus is on bringing transparency, scientific rigor, and practical guidance to the hyperbaric oxygen therapy space.
